Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial
| Autor: | Areoo Samaei, Amir Ashraf-Ganjouei, Farzin Rezaei, Sayna Bagheri, Rosa Alikhani, Seiedeh Bentolhoda Mousavi, Kamyar Moradi, Shahin Akhondzadeh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty AcademicSubjects/MED00415 Placebo-controlled study resveratrol Placebo Regular Research Articles Antioxidants Extrapyramidal symptoms Double-Blind Method Internal medicine Outcome Assessment Health Care medicine Humans Pharmacology (medical) Pharmacology Risperidone Positive and Negative Syndrome Scale business.industry AcademicSubjects/SCI01870 primary negative symptoms clinical trial Middle Aged medicine.disease Clinical trial schizophrenia Psychiatry and Mental health Tolerability Schizophrenia Drug Therapy Combination Female medicine.symptom business medicine.drug Antipsychotic Agents |
| Zdroj: | International Journal of Neuropsychopharmacology |
| ISSN: | 1469-5111 1461-1457 |
| Popis: | Background Patients with schizophrenia can generally manifest a broad variety of primary negative symptoms. The current study aimed to assess the efficacy and tolerability of resveratrol add-on therapy in the treatment of negative symptoms in patients with stable schizophrenia. Methods In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks. Patients were assessed using the positive and negative syndrome scale, the extrapyramidal symptom rating scale, and Hamilton Depression Rating Scale over the trial period. The primary outcome was considered as the change in positive and negative subscale score from baseline to week 8 between the treatment arms. Results A total 52 patients completed the trial (26 in each arm). Baseline characteristics of both groups were statistically similar (P > .05). Despite the statistically similar behavior of positive symptoms between the groups across time (Greenhouse-Geisser corrected: F = 1.76, df = 1.88, P = .180), the resveratrol group demonstrated greater improvement in negative, general psychopathology, and total scores (Greenhouse-Geisser corrected: F = 12.25, df = 2.04, P Conclusion Adding resveratrol to risperidone can exhibit remarkable efficacy and safety in terms of management of schizophrenia-related negative symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|